Ondem

Quick links to important sections

Ondem

Method of action: Anti-Abstinence, Antiemetic

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ondem

Quick Facts: Ondansetron Identity

Property Description
Active Ingredient Ondansetron (typically as the hydrochloride salt)
Forms Tablets, Oral Solution, Injectable Solution (Ampoules)
Pharmacological Class Selective Serotonin 5-HT3 Receptor Antagonist
Common Use Prevention and relief of nausea and vomiting
Origin Synthetic compound

The Identity and Composition of Ondansetron

The commercial preparation Ondem contains the active ingredient Ondansetron, a synthetic compound derived from the carbazole family. The drug operates as a single active ingredient product, with its function wholly dependent on the properties of the Ondansetron molecule. This molecule targets chemical signaling pathways with high selectivity.

Classification and Primary Purpose

Ondansetron is categorized as a potent Antiemetic belonging to the pharmacological class of selective serotonin 5-HT3 receptor antagonists. This highly specific classification means the medicine works by blocking the chemical messenger serotonin from activating its designated 5-HT3 receptors, which are crucial signaling points for the sickness reflex. The essential general purpose of this antagonism is the efficient prevention and relief of nausea and vomiting, such as that associated with certain necessary medical treatments.

In What Forms is Ondansetron Available?

Ondansetron is manufactured in multiple high-level dosage forms. These preparations include solid forms for oral intake, such as standard Tablets and specialized Orodispersible Tablets (ODT). Additionally, the drug is available as an Injectable Solution (in Ampoules) for Intravenous administration. This dual availability is a standard feature of this compound, which supports its broad use in various care settings.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Ondem?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety constraints of Ondansetron (Ondem) as documented in official government regulatory information.

Frequency-Classified Side Effects

Adverse reactions are classified based on how often they occur:

  • Very Common (Affects more than 1 in 10 people): Headache.
  • Common (Affects up to 1 in 10 people): Constipation, sensation of warmth or flushing.
  • Uncommon: Seizures, involuntary movement disorders, arrhythmias, chest pain, and temporary increases in liver function tests.

Serious Adverse Reactions

Serious reactions, while rare, are documented in regulatory labeling and require immediate medical attention:

  • Cardiac Events: Ondansetron can cause QTc interval prolongation, which may lead to a life-threatening irregular heart rhythm called Torsade de Pointes. This risk is dose-dependent.
  • Hypersensitivity: Rare, but potentially severe allergic reactions, including anaphylaxis.
  • Serotonin Syndrome: Reported with Ondansetron, especially when used with other medicines that affect serotonin levels.

Population-Specific Safety and Restrictions

  • Severe Liver Impairment: The maximum recommended daily dose is restricted to 8 mg due to reduced clearance in patients with severe hepatic impairment.
  • Pregnancy: Epidemiological studies suggest a potential risk of orofacial malformations (such as oral clefts) if used during the first trimester.
  • Contraindications: Ondansetron must not be used concomitantly with Apomorphine (used to treat Parkinson's disease) due to the risk of profound hypotension and loss of consciousness. It is also advised to avoid use in patients with congenital long QT syndrome.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Ondansetron is formally documented as carrying risks for severe systemic toxicity, necessitating immediate medical evaluation. Regulatory guidance describes the required actions and clinical manifestations.

Documented Overdose Presentations

Regulatory sources indicate that an overdose may present with cardiovascular symptoms such as hypotension, vasovagal episodes, and a transient second-degree AV block. Other reported manifestations include severe constipation, somnolence, and short-lived episodes of sudden blindness (amaurosis).

Severe and Life-Threatening Outcomes

The most critical documented risks are associated with cardiac and central nervous system effects. Overdoses carry a risk of dose-dependent QT interval prolongation on the ECG, which may lead to the potentially fatal arrhythmia known as Torsades de Pointes. Neurological complications include seizure and signs consistent with Serotonin Syndrome (e.g., hyperreflexia, agitation, tachycardia).

Required Emergency Actions

Individuals must seek immediate medical attention if they experience symptoms consistent with severe cardiac or neurological toxicity, such as an irregular heartbeat, dizziness, or fainting (syncope). Management is strictly symptomatic and supportive therapy, as no specific antidote is known. ECG monitoring is recommended due to the documented cardiac risks. Increased toxicity, including Serotonin Syndrome and QTc prolongation, has been specifically noted in infants and toddlers following accidental ingestion.

Therapeutic Uses of Ondem

What Ondem Treats: Main Uses and Benefits

Ondansetron is commonly applied across specific therapeutic domains where supportive symptom management is appropriate. This medication may be part of symptomatic management designed to manage some of the most challenging manifestations of nausea and vomiting. It contributes to easing the overall symptom burden in situations where patients experience heightened distress.

The primary therapeutic applications include addressing nausea and vomiting induced by certain chemotherapy agents, sickness related to radiation therapy, and acute symptoms associated with Postoperative Nausea and Vomiting (PONV) following anesthesia and surgical stress. It is also relevant in specialized contexts, and may be considered for addressing severe sickness associated with pregnancy (Hyperemesis Gravidarum) and challenging nausea in advanced illnesses.

This focus on easing discomfort assists with providing supportive relief when symptoms interfere with routine activities, and may assist with maintaining functional stability, supporting general well-being during symptomatic phases.


Quick Fact: Relief for Severe Sickness
Symptoms the Medication May Help Ease Severe or persistent nausea, intractable vomiting (emesis), and breakthrough sickness.
Common Scenarios Used in oncology settings, perioperative care, and for managing severe, refractory emesis in specialized contexts.
Core Patient Benefit Provides support that helps ease the overall symptom burden.

Regulatory References

  1. NIH MedlinePlus overview of Ondansetron

Eligibility and Restrictions for Use

This section outlines official population-eligibility rules based on government regulatory labeling, specifying groups for whom the medicine is contraindicated or restricted.

Absolute Contraindications

Ondansetron is contraindicated in patients with a known hypersensitivity to the drug or any component of the formulation. Use is also prohibited in patients receiving concomitant apomorphine due to the reported risk of profound hypotension and loss of consciousness.

Age and Condition Restrictions

Population Group Regulatory Eligibility Status
Pediatric Use Approved for chemotherapy-induced nausea/vomiting (CINV) from 6 months of age and for postoperative nausea/vomiting (PONV) from 1 month of age.
Severe Hepatic Impairment Restricted Use: The total daily dose must not exceed 8 mg.
Cardiac Conditions Use should be avoided in patients with known congenital long QT syndrome.
Pregnancy (First Trimester) Not Recommended: European labeling advises against use during the first trimester.
Breastfeeding Not Recommended: It is unknown if the medicine is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Before taking Ondem (ondansetron), it is essential to discuss all prescription and non-prescription products, including herbal supplements, with a healthcare professional, as certain combinations can lead to significant interactions.

Contraindicated Combination

Ondem must not be used concurrently with apomorphine, a medication used for Parkinson’s disease. This combination is linked to reports of profound drops in blood pressure (hypotension) and loss of consciousness.

Risk of Serotonin Syndrome

Concomitant use of Ondem with other drugs that increase serotonin levels, such as Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), and certain other serotonergic medications, carries a risk of serotonin syndrome. This is a serious condition with symptoms that can include agitation, rapid heart rate, confusion, and muscle stiffness. Patients should be closely monitored for these signs.

Cardiac Risk

Ondem can affect the heart’s electrical activity, potentially causing a rare but serious change called QT interval prolongation, which may lead to life-threatening heart rhythms. This risk is increased when Ondem is taken with other medicines that also prolong the QT interval or in individuals with pre-existing heart conditions like congenital long QT syndrome, for whom Ondem is typically avoided. Patients with specific electrolyte imbalances, such as low potassium or magnesium, should also be monitored closely.

Interactions Affecting Drug Levels

Medicines that are potent inducers of a liver enzyme called CYP3A4, such as phenytoin, carbamazepine, or rifampicin, can significantly increase the breakdown and clearance of ondansetron from the body, leading to lower blood levels of Ondem.

Mechanism of Action

Selective Blockade of the Serotonin 5-HT3 Receptor

Ondansetron functions as a selective competitive antagonist for the serotonin 5- HT3 receptor, a ligand-gated ion channel. This mechanism is defined by the drug's competitive binding to the receptor site, which inhibits the endogenous neurotransmitter serotonin (5-HT) from activating the channel. This interaction blocks the neural signal transmission and directly modulates pathways associated with the initiation of the sickness reflex.

Dual Central and Peripheral Emetic Signal Interruption

The physiological effect results from a dual blockade across the nervous system. The drug suppresses afferent signals originating in the gastrointestinal tract (peripheral vagal nerve terminals) and simultaneously blocks circulating triggers in the Chemoreceptor Trigger Zone (CTZ) of the brainstem. By interrupting the neural signal flow at both peripheral and central points, the mechanism modulates the final activation of the medullary vomiting center.

Mechanism Limitation: Specificity for 5-HT3 Pathway

The functional scope is defined by its specificity for the 5-HT3 receptor, meaning its action is confined to pathways mediated by serotonin. The mechanism influences the 5-HT3 system but does not modulate activity in non-targeted pathways; consequently, its physiological effect is minimal when other mediators dominate the response.

Dosage and Administration Information

Standard Administration Guidelines for Ondem (Ondansetron)

Ondem is administered via multiple routes, including oral (tablet, oral solution, or orally disintegrating tablet) and parenteral (Intravenous/Intramuscular injection), strictly according to the condition being treated and the patient's age and health status. The first dose is typically prophylactic, meaning it is given before the start of the procedure.

Administration Scope General Administration Instructions
Route of Administration Oral, Intravenous (IV), or Intramuscular (IM) injection.
Frequency Pattern Can be a single dose (e.g., Postoperative Nausea/Vomiting prevention) or multiple doses over 1 to 5 days (e.g., Chemotherapy-Induced Nausea and Vomiting).
Timing Initial dose is usually administered 30 minutes before chemotherapy or one hour before anesthesia induction for surgery.
Preparation IV doses for chemotherapy must be diluted in compatible intravenous fluid (e.g., 0.9% Sodium Chloride Injection) and infused over at least 15 minutes. Oral solutions should be measured with a dedicated dosing device.
Special Conditions Orally Disintegrating Tablets (ODT) and films must be placed on the tongue to dissolve and swallowed with saliva, without water. The total daily dose must not exceed 8 mg in patients with severe hepatic impairment.
Age-Specific Dosing Pediatric dosing (aged 6 months or greater for CINV) is often calculated based on Body Surface Area (mg/m^2) or body weight (mg/kg), with a maximum single dose often specified.

Procedural Sequence (IV Infusion Example): For chemotherapy, the initial IV dose must be diluted and administered as an infusion over a 15-minute period, starting 30 minutes before the cytotoxic agent. This is followed by repeat doses at subsequent scheduled intervals, such as 4 and 8 hours after the initial dose, if a multi-dose regimen is prescribed. Strict adherence to the mandated rate of infusion (e.g., 15 minutes or more for larger doses) is required for patient safety.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ondem

Evidence for Use in Chemotherapy-Induced Nausea and Vomiting (CINV)

The evidence base for research into sickness related to cancer treatment is available. Research has primarily focused on Randomized Controlled Trials (RCTs), which are considered a high standard for clinical evidence, supported by systematic reviews and meta-analyses. These studies have explored the drug's role in two specific timeframes: the acute phase (within the first 24 hours after treatment) and the delayed phase (the days immediately following).

Researchers examined patient groups receiving different types of chemotherapy. The primary study endpoints included measurements of the number of vomiting episodes and tracking the severity and duration of nausea using patient-reported scales. The findings describe patterns observed in the studies where, in the short-term acute phase, the medicine was evaluated in research exploring short-term symptom changes compared to other treatments or a placebo.

Evidence for Use in Postoperative Nausea and Vomiting (PONV)

For managing sickness that occurs after surgery and anesthesia, the evidence primarily comes from Randomized Controlled Trials (RCTs) that studied short-term outcomes. These studies were evaluated in surgical settings to help manage episodic or acute changes in patient comfort. Studies monitored a wide range of adults and children undergoing different types of surgical procedures.

The research examined outcomes related to physical discomfort, focusing mainly on the first 24 hours following the operation. The findings describe patterns observed in the studies where, when given before or shortly after surgery, researchers monitored outcomes capturing phases of heightened symptom activity compared to those receiving a placebo.

Limitations and Research Gaps

Despite the significant body of evidence, research highlights what is known—and what is still uncertain. Comparative evidence is lacking for many direct head-to-head comparisons against newer anti-sickness medications that use different mechanisms of action. This means the relative performance against the most recent treatments is not fully established.

Furthermore, research is still emerging regarding the studied use of the drug in complex or difficult-to-treat situations. The subgroup findings are uncertain for individuals with specific pre-existing conditions; research continues to explore outcomes related to physiological strain or stress in various settings.

Frequently Asked Questions (FAQ)

Common questions about Ondem (FAQ)


Q: Can Ondem be taken on an empty stomach?

According to official drug information, Ondansetron (the active ingredient in Ondem) can be administered with or without food. Although the presence of food may slightly enhance the absorption of the medicine, this is usually not considered a significant clinical factor, and it can typically be administered regardless of a patient's meal schedule, as indicated by prescribing information.


Q: Is it normal to feel a bit dizzy after taking Ondem?

Dizziness and lightheadedness are potential side effects listed in official safety information for Ondansetron. Because of this, official patient instructions often advise caution regarding changes in position, as dizziness may occur.


Q: Does Ondem cause drowsiness or make you sleepy?

Yes, regulatory documents list drowsiness or sleepiness (somnolence) as a possible side effect of Ondansetron. Patients should be aware of this potential effect, especially when starting the medication.


Q: Is it safe to drive after taking Ondem?

Official patient guidance advises against driving, operating machinery, or participating in other dangerous activities until the individual knows how the medication affects them. This caution is due to the potential for side effects like dizziness or sleepiness, which could impair safe functioning.


Q: Is it okay to crush or chew the Ondem tablet?

The standard tablet is generally intended to be swallowed whole, and official instructions typically advise against crushing, chewing, or splitting it. If the specialized Orally Disintegrating Tablet (ODT) form is prescribed, it is intended to be placed on the tongue to dissolve, as outlined in its instructions for use.


Q: What happens if you miss a dose of Ondem?

Regulatory guidance for a missed dose generally advises patients to take it as soon as it is remembered, unless the next dose is due shortly. If close to the next scheduled time, the missed dose should typically be skipped to avoid taking two doses too close together. This is standard guidance to prevent double-dosing.


Q: What research supports the use of Ondem for gastroenteritis?

While the drug is primarily approved for sickness related to chemotherapy and surgery, the use of a single oral dose has been described in professional literature related to managing severe cases of acute gastroenteritis (stomach flu). Routine use for this condition is often not a primary recommendation.


Q: Does Ondem have any effect on blood pressure?

Regulatory warnings indicate that when Ondansetron is taken concurrently with apomorphine (used for Parkinson’s disease), there have been reports of profound drops in blood pressure (hypotension). There are no specific warnings for Ondansetron alone causing high blood pressure.


Q: Is it safe to take Ondem if I have kidney issues?

Official prescribing information indicates that dose modification or a change in dosing frequency is generally not necessary for patients with kidney (renal) impairment. This is because, while the body's clearance of the medicine may be reduced in severe cases, the reduction is not considered clinically significant enough to warrant a change in dose.


Q: Does Ondem interfere with oral contraceptives?

Official drug interaction information generally reports no known significant interactions between Ondansetron and the components of common oral contraceptives. However, the need for appropriate contraception during treatment is often noted in guidance for women of childbearing potential.


Q: What is the typical duration of treatment with Ondem?

For its major approved uses, such as preventing sickness from chemotherapy or surgery, treatment with Ondansetron is typically short-term. Depending on the regimen, official product information specifies a duration ranging from a single dose up to multiple doses given over a period of 1 to 5 days.


Q: Can Ondem be taken with pain relievers like paracetamol or ibuprofen?

Official drug interaction databases generally report no known significant interactions between Ondansetron and common over-the-counter pain relievers such as paracetamol (acetaminophen) or ibuprofen. This indicates the combination is generally not a major concern based on current data.


Q: Is it normal to experience mild tiredness on Ondem?

Yes, official drug information lists general weakness or tiredness (known medically as asthenia) as a possible side effect of Ondansetron. Patients should be aware of this potential side effect, although it is not considered one of the most common reactions.

How should Ondem be stored and disposed of?

Storage and Disposal of Ondansetron (Ondem)

Storage Scope Official Regulatory Requirements
Temperature Store most forms at 20 C to 25 C (68 F to 77 F), often defined as Controlled Room Temperature.
Environmental Protection Protect from light and moisture. The injection and oral solution must not be frozen.
Packaging Keep the medicine in the original container and often retained in the outer carton until use. Oral solution containers must be kept tightly closed.
Stability (Injection) After dilution, the solution must not be used beyond 24 hours due to the need for sterile precautions.

All Ondansetron formulations must be kept out of the sight and reach of children to prevent accidental exposure. For disposal, unused or expired product must be discarded in accordance with local requirements. Official guidance restricts disposal via household waste or wastewater to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ondem found in:

A-Z Index: